nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—CYP1A1—liver cancer	0.574	1	CbGaD
Isoprenaline—Tachyarrhythmia—Epirubicin—liver cancer	7.86e-05	0.146	CcSEcCtD
Isoprenaline—Tachyarrhythmia—Doxorubicin—liver cancer	7.27e-05	0.135	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Epirubicin—liver cancer	1.94e-05	0.0361	CcSEcCtD
Isoprenaline—Flushing—Sorafenib—liver cancer	1.81e-05	0.0337	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Doxorubicin—liver cancer	1.79e-05	0.0334	CcSEcCtD
Isoprenaline—Arrhythmia—Sorafenib—liver cancer	1.74e-05	0.0324	CcSEcCtD
Isoprenaline—Hypertension—Sorafenib—liver cancer	1.47e-05	0.0273	CcSEcCtD
Isoprenaline—Pulmonary oedema—Epirubicin—liver cancer	1.28e-05	0.0238	CcSEcCtD
Isoprenaline—Dyspnoea—Sorafenib—liver cancer	1.24e-05	0.023	CcSEcCtD
Isoprenaline—Pulmonary oedema—Doxorubicin—liver cancer	1.18e-05	0.022	CcSEcCtD
Isoprenaline—Asthenia—Sorafenib—liver cancer	9.94e-06	0.0185	CcSEcCtD
Isoprenaline—Cardiac arrest—Epirubicin—liver cancer	9.91e-06	0.0185	CcSEcCtD
Isoprenaline—Cardiac arrest—Doxorubicin—liver cancer	9.17e-06	0.0171	CcSEcCtD
Isoprenaline—Dizziness—Sorafenib—liver cancer	9.16e-06	0.0171	CcSEcCtD
Isoprenaline—Angina pectoris—Epirubicin—liver cancer	8.77e-06	0.0163	CcSEcCtD
Isoprenaline—Headache—Sorafenib—liver cancer	8.68e-06	0.0162	CcSEcCtD
Isoprenaline—Nausea—Sorafenib—liver cancer	8.23e-06	0.0153	CcSEcCtD
Isoprenaline—Angina pectoris—Doxorubicin—liver cancer	8.12e-06	0.0151	CcSEcCtD
Isoprenaline—Sweating—Epirubicin—liver cancer	7.7e-06	0.0143	CcSEcCtD
Isoprenaline—Sweating—Doxorubicin—liver cancer	7.12e-06	0.0133	CcSEcCtD
Isoprenaline—MAPK1—Disease—PIK3CB—liver cancer	6.74e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MTOR—liver cancer	6.74e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—H2AFX—liver cancer	6.73e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—IL2—liver cancer	6.73e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL2—liver cancer	6.7e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—Flushing—Epirubicin—liver cancer	6.69e-06	0.0125	CcSEcCtD
Isoprenaline—PIK3R2—Signaling Pathways—VEGFA—liver cancer	6.68e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KDR—liver cancer	6.68e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GOT1—liver cancer	6.66e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GGT1—liver cancer	6.66e-06	1.57e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CB—liver cancer	6.66e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MAPK14—liver cancer	6.64e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—HRAS—liver cancer	6.62e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—STAT3—liver cancer	6.62e-06	1.56e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—IL6—liver cancer	6.6e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—AKT1—liver cancer	6.6e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—VEGFA—liver cancer	6.58e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—KRAS—liver cancer	6.57e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—PIK3CA—liver cancer	6.55e-06	1.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—PIK3CA—liver cancer	6.54e-06	1.54e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—STAT3—liver cancer	6.52e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—JUN—liver cancer	6.52e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CDKN1B—liver cancer	6.51e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—ESR1—liver cancer	6.51e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—IL6—liver cancer	6.5e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—AKT1—liver cancer	6.5e-06	1.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CTNNB1—liver cancer	6.47e-06	1.52e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—HRAS—liver cancer	6.47e-06	1.52e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—GPCR downstream signaling—AKT1—liver cancer	6.44e-06	1.51e-05	CbGpPWpGaD
Isoprenaline—Arrhythmia—Epirubicin—liver cancer	6.44e-06	0.012	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—F2—liver cancer	6.43e-06	1.51e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Metabolism—AKT1—liver cancer	6.4e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CASP3—liver cancer	6.38e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL2—liver cancer	6.37e-06	1.5e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CDKN1B—liver cancer	6.36e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—IL6—liver cancer	6.34e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—TP53—liver cancer	6.34e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CDKN1B—liver cancer	6.32e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CDKN1A—liver cancer	6.32e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—ADRB3—GPCR downstream signaling—AKT1—liver cancer	6.29e-06	1.48e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL2—liver cancer	6.25e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—PIK3CA—liver cancer	6.24e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—AKT1—liver cancer	6.24e-06	1.47e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CASP3—liver cancer	6.23e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TERT—liver cancer	6.23e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL2—liver cancer	6.22e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CCND1—liver cancer	6.21e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—JUN—liver cancer	6.2e-06	1.46e-05	CbGpPWpGaD
Isoprenaline—Flushing—Doxorubicin—liver cancer	6.19e-06	0.0115	CcSEcCtD
Isoprenaline—ADRB3—Signaling by GPCR—IL6—liver cancer	6.19e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—MAPK8—liver cancer	6.17e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—Tension—Epirubicin—liver cancer	6.16e-06	0.0115	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—APC—liver cancer	6.16e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CG—liver cancer	6.16e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CTNNB1—liver cancer	6.15e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—MYC—liver cancer	6.15e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TGFB1—liver cancer	6.13e-06	1.44e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL2—liver cancer	6.11e-06	1.44e-05	CbGpPWpGaD
Isoprenaline—Nervousness—Epirubicin—liver cancer	6.09e-06	0.0113	CcSEcCtD
Isoprenaline—ADRB2—Signaling Pathways—TERT—liver cancer	6.09e-06	1.43e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—AKT1—liver cancer	6.09e-06	1.43e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CCND1—liver cancer	6.06e-06	1.43e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—HRAS—liver cancer	6.06e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—MYC—liver cancer	6.06e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—HRAS—liver cancer	6.05e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—JUN—liver cancer	6.05e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TGFB1—liver cancer	6.04e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—PIK3CA—liver cancer	6.04e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MMP9—liver cancer	6.03e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CDKN1A—liver cancer	6.01e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CTNNB1—liver cancer	6e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—AKT1—liver cancer	6e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTP1—liver cancer	5.98e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CTNNB1—liver cancer	5.97e-06	1.4e-05	CbGpPWpGaD
Isoprenaline—Arrhythmia—Doxorubicin—liver cancer	5.96e-06	0.0111	CcSEcCtD
Isoprenaline—Vision blurred—Epirubicin—liver cancer	5.91e-06	0.011	CcSEcCtD
Isoprenaline—CYP1A1—Metabolism—HMOX1—liver cancer	5.9e-06	1.39e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MMP9—liver cancer	5.89e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CDKN1A—liver cancer	5.87e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MAPK8—liver cancer	5.87e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—AKT1—liver cancer	5.85e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CDKN1A—liver cancer	5.83e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL6—liver cancer	5.8e-06	1.36e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL6—liver cancer	5.79e-06	1.36e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—BRAF—liver cancer	5.79e-06	1.36e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MAPK8—liver cancer	5.73e-06	1.35e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—AKT1—liver cancer	5.71e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—Tension—Doxorubicin—liver cancer	5.7e-06	0.0106	CcSEcCtD
Isoprenaline—ADRB1—Signaling Pathways—KDR—liver cancer	5.69e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—liver cancer	5.68e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MAPK14—liver cancer	5.66e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—Nervousness—Doxorubicin—liver cancer	5.64e-06	0.0105	CcSEcCtD
Isoprenaline—MAPK1—Immune System—STAT3—liver cancer	5.64e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—Vertigo—Epirubicin—liver cancer	5.64e-06	0.0105	CcSEcCtD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—liver cancer	5.6e-06	1.32e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—HRAS—liver cancer	5.59e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KDR—liver cancer	5.57e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ESR1—liver cancer	5.55e-06	1.3e-05	CbGpPWpGaD
Isoprenaline—Palpitations—Epirubicin—liver cancer	5.54e-06	0.0103	CcSEcCtD
Isoprenaline—ADRB2—Signaling Pathways—MAPK14—liver cancer	5.53e-06	1.3e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTM1—liver cancer	5.5e-06	1.29e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—F2—liver cancer	5.48e-06	1.29e-05	CbGpPWpGaD
Isoprenaline—Vision blurred—Doxorubicin—liver cancer	5.47e-06	0.0102	CcSEcCtD
Isoprenaline—Convulsion—Epirubicin—liver cancer	5.44e-06	0.0101	CcSEcCtD
Isoprenaline—ADRB2—Signaling Pathways—ESR1—liver cancer	5.43e-06	1.28e-05	CbGpPWpGaD
Isoprenaline—Hypertension—Epirubicin—liver cancer	5.42e-06	0.0101	CcSEcCtD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—liver cancer	5.42e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CD—liver cancer	5.41e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—F2—liver cancer	5.36e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—STAT3—liver cancer	5.36e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SERPINE1—liver cancer	5.35e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—AKT1—liver cancer	5.35e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IL6—liver cancer	5.35e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—AKT1—liver cancer	5.34e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—liver cancer	5.3e-06	1.25e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—liver cancer	5.29e-06	1.24e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CG—liver cancer	5.25e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—APC—liver cancer	5.25e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—STAT3—liver cancer	5.23e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—PIK3CA—liver cancer	5.22e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—Vertigo—Doxorubicin—liver cancer	5.22e-06	0.00971	CcSEcCtD
Isoprenaline—MAPK1—Disease—STAT3—liver cancer	5.21e-06	1.22e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—PIK3CA—liver cancer	5.14e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CG—liver cancer	5.13e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—APC—liver cancer	5.13e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—Palpitations—Doxorubicin—liver cancer	5.13e-06	0.00956	CcSEcCtD
Isoprenaline—PIK3R2—Metabolism—AKT1—liver cancer	5.1e-06	1.2e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PIK3CA—liver cancer	5.06e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—liver cancer	5.05e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—Convulsion—Doxorubicin—liver cancer	5.03e-06	0.00937	CcSEcCtD
Isoprenaline—Hypertension—Doxorubicin—liver cancer	5.01e-06	0.00934	CcSEcCtD
Isoprenaline—Tachycardia—Epirubicin—liver cancer	5e-06	0.00931	CcSEcCtD
Isoprenaline—PIK3R1—Signaling Pathways—MYC—liver cancer	4.98e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—liver cancer	4.97e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TGFB1—liver cancer	4.97e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—Hyperhidrosis—Epirubicin—liver cancer	4.95e-06	0.00922	CcSEcCtD
Isoprenaline—PIK3R1—Disease—AKT1—liver cancer	4.93e-06	1.16e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—BRAF—liver cancer	4.93e-06	1.16e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—PIK3CA—liver cancer	4.87e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MYC—liver cancer	4.86e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—MTHFR—liver cancer	4.86e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TGFB1—liver cancer	4.85e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—liver cancer	4.84e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MYC—liver cancer	4.84e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—RAF1—liver cancer	4.83e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—HRAS—liver cancer	4.83e-06	1.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—TGFB1—liver cancer	4.83e-06	1.13e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—BRAF—liver cancer	4.82e-06	1.13e-05	CbGpPWpGaD
Isoprenaline—Hypotension—Epirubicin—liver cancer	4.79e-06	0.00891	CcSEcCtD
Isoprenaline—CYP1A1—Metabolism—PPARA—liver cancer	4.77e-06	1.12e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—HRAS—liver cancer	4.76e-06	1.12e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CB—liver cancer	4.72e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MTOR—liver cancer	4.72e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—Insomnia—Epirubicin—liver cancer	4.63e-06	0.00863	CcSEcCtD
Isoprenaline—Tachycardia—Doxorubicin—liver cancer	4.62e-06	0.00861	CcSEcCtD
Isoprenaline—PIK3R2—Signaling Pathways—IL6—liver cancer	4.62e-06	1.09e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CD—liver cancer	4.61e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—liver cancer	4.6e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—Hyperhidrosis—Doxorubicin—liver cancer	4.58e-06	0.00853	CcSEcCtD
Isoprenaline—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	4.57e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—Dyspnoea—Epirubicin—liver cancer	4.57e-06	0.0085	CcSEcCtD
Isoprenaline—ADRB1—Signaling Pathways—SERPINE1—liver cancer	4.56e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL6—liver cancer	4.55e-06	1.07e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—liver cancer	4.52e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CD—liver cancer	4.51e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—HRAS—liver cancer	4.5e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—liver cancer	4.49e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—liver cancer	4.47e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—PIK3CA—liver cancer	4.47e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SERPINE1—liver cancer	4.46e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—PIK3CA—liver cancer	4.45e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—Hypotension—Doxorubicin—liver cancer	4.43e-06	0.00825	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—CDKN1B—liver cancer	4.43e-06	1.04e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—liver cancer	4.42e-06	1.04e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CASP3—liver cancer	4.34e-06	1.02e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL2—liver cancer	4.33e-06	1.02e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL6—liver cancer	4.31e-06	1.01e-05	CbGpPWpGaD
Isoprenaline—Insomnia—Doxorubicin—liver cancer	4.29e-06	0.00798	CcSEcCtD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.28e-06	1.01e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—AKT1—liver cancer	4.26e-06	1e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PIK3CA—liver cancer	4.23e-06	9.94e-06	CbGpPWpGaD
Isoprenaline—Dyspnoea—Doxorubicin—liver cancer	4.22e-06	0.00787	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—CCND1—liver cancer	4.22e-06	9.93e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—JUN—liver cancer	4.21e-06	9.9e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—AKT1—liver cancer	4.2e-06	9.87e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CTNNB1—liver cancer	4.18e-06	9.83e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	4.15e-06	9.75e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—AKT1—liver cancer	4.13e-06	9.71e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PIK3CA—liver cancer	4.13e-06	9.7e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—RAF1—liver cancer	4.12e-06	9.68e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—HRAS—liver cancer	4.11e-06	9.67e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PIK3CA—liver cancer	4.11e-06	9.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MMP9—liver cancer	4.1e-06	9.64e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—liver cancer	4.09e-06	9.62e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CDKN1A—liver cancer	4.08e-06	9.6e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CG—liver cancer	4.08e-06	9.6e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CA—liver cancer	4.06e-06	9.54e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—RAF1—liver cancer	4.03e-06	9.47e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MTOR—liver cancer	4.02e-06	9.45e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CB—liver cancer	4.02e-06	9.45e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—liver cancer	3.99e-06	9.39e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MAPK8—liver cancer	3.99e-06	9.37e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—AKT1—liver cancer	3.98e-06	9.35e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PPARG—liver cancer	3.94e-06	9.26e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL6—liver cancer	3.94e-06	9.26e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CB—liver cancer	3.93e-06	9.24e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MTOR—liver cancer	3.93e-06	9.24e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—HRAS—liver cancer	3.91e-06	9.2e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—HRAS—liver cancer	3.84e-06	9.02e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—HRAS—liver cancer	3.82e-06	8.98e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—HRAS—liver cancer	3.8e-06	8.93e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CDKN1B—liver cancer	3.77e-06	8.87e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—HRAS—liver cancer	3.75e-06	8.82e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL6—liver cancer	3.75e-06	8.8e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—AKT1—liver cancer	3.73e-06	8.77e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CASP3—liver cancer	3.7e-06	8.69e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL2—liver cancer	3.69e-06	8.68e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CDKN1B—liver cancer	3.69e-06	8.67e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—liver cancer	3.68e-06	8.65e-06	CbGpPWpGaD
Isoprenaline—Asthenia—Epirubicin—liver cancer	3.67e-06	0.00684	CcSEcCtD
Isoprenaline—ADRB1—Signaling by GPCR—IL6—liver cancer	3.67e-06	8.63e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL6—liver cancer	3.66e-06	8.59e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—AKT1—liver cancer	3.65e-06	8.58e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—STAT3—liver cancer	3.65e-06	8.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IL6—liver cancer	3.64e-06	8.55e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—AKT1—liver cancer	3.63e-06	8.54e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CASP3—liver cancer	3.62e-06	8.5e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL2—liver cancer	3.61e-06	8.49e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CCND1—liver cancer	3.6e-06	8.46e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL6—liver cancer	3.59e-06	8.45e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—JUN—liver cancer	3.59e-06	8.44e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CD—liver cancer	3.59e-06	8.44e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CTNNB1—liver cancer	3.56e-06	8.38e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ALB—liver cancer	3.54e-06	8.33e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CCND1—liver cancer	3.52e-06	8.27e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—JUN—liver cancer	3.51e-06	8.26e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MMP9—liver cancer	3.49e-06	8.21e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CTNNB1—liver cancer	3.49e-06	8.19e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CDKN1A—liver cancer	3.48e-06	8.18e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—AKT1—liver cancer	3.46e-06	8.12e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MMP9—liver cancer	3.42e-06	8.03e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CDKN1A—liver cancer	3.41e-06	8e-06	CbGpPWpGaD
Isoprenaline—Asthenia—Doxorubicin—liver cancer	3.4e-06	0.00633	CcSEcCtD
Isoprenaline—ADRB1—Signaling Pathways—MAPK8—liver cancer	3.4e-06	7.99e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—AKT1—liver cancer	3.39e-06	7.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MYC—liver cancer	3.39e-06	7.96e-06	CbGpPWpGaD
Isoprenaline—Dizziness—Epirubicin—liver cancer	3.39e-06	0.00631	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—TGFB1—liver cancer	3.38e-06	7.94e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—AKT1—liver cancer	3.37e-06	7.93e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—AKT1—liver cancer	3.35e-06	7.88e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MAPK8—liver cancer	3.32e-06	7.81e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—AKT1—liver cancer	3.31e-06	7.79e-06	CbGpPWpGaD
Isoprenaline—Headache—Epirubicin—liver cancer	3.21e-06	0.00597	CcSEcCtD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—liver cancer	3.14e-06	7.37e-06	CbGpPWpGaD
Isoprenaline—Dizziness—Doxorubicin—liver cancer	3.13e-06	0.00584	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—liver cancer	3.13e-06	7.36e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CB—liver cancer	3.13e-06	7.35e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—STAT3—liver cancer	3.11e-06	7.3e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—liver cancer	3.07e-06	7.21e-06	CbGpPWpGaD
Isoprenaline—Nausea—Epirubicin—liver cancer	3.04e-06	0.00566	CcSEcCtD
Isoprenaline—ADRB2—Signaling Pathways—STAT3—liver cancer	3.04e-06	7.14e-06	CbGpPWpGaD
Isoprenaline—Headache—Doxorubicin—liver cancer	2.97e-06	0.00553	CcSEcCtD
Isoprenaline—ADRB1—Signaling Pathways—MYC—liver cancer	2.89e-06	6.79e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TGFB1—liver cancer	2.88e-06	6.77e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CA—liver cancer	2.88e-06	6.76e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MYC—liver cancer	2.82e-06	6.64e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TGFB1—liver cancer	2.82e-06	6.62e-06	CbGpPWpGaD
Isoprenaline—Nausea—Doxorubicin—liver cancer	2.81e-06	0.00524	CcSEcCtD
Isoprenaline—MAPK1—Signaling Pathways—TP53—liver cancer	2.78e-06	6.54e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—liver cancer	2.67e-06	6.27e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HRAS—liver cancer	2.66e-06	6.25e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—liver cancer	2.61e-06	6.13e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6—liver cancer	2.55e-06	5.98e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CA—liver cancer	2.45e-06	5.76e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CA—liver cancer	2.4e-06	5.63e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—liver cancer	2.37e-06	5.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKT1—liver cancer	2.35e-06	5.52e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—liver cancer	2.32e-06	5.45e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HRAS—liver cancer	2.27e-06	5.33e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HRAS—liver cancer	2.22e-06	5.21e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6—liver cancer	2.17e-06	5.1e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6—liver cancer	2.12e-06	4.99e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKT1—liver cancer	2e-06	4.71e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKT1—liver cancer	1.96e-06	4.6e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CA—liver cancer	1.91e-06	4.48e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKT1—liver cancer	1.56e-06	3.66e-06	CbGpPWpGaD
